FDA Approves New Combo Breast Cancer Treatment for Subcutaneous Injection

July 01, 2020

The fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase (Phesgo; Genentech) can be administered subcutaneously for patients with HER2-positive breast cancer.

Pharmacists: Fight Racial Disparities in Health Care

June 26, 2020

Today, pharmacists are banding together to “eliminate racism, discrimination, injustice, and the marginalization of individuals within the profession.”

Ribociclib Shows Overall Survival Benefit in Patients With Advanced Breast Cancer With Visceral Metastases

June 11, 2020

An exploratory analysis of 2 phase 3 trials evaluating ribociclib (Kisqali, Novartis) plus endocrine therapy in advanced breast cancer showed positive results.

Survey: Oncology Pharmacists Report Impaired Access to PPE, Certain Medications

June 10, 2020

Oncology pharmacy practitioners highlight challenges amid the pandemic, such as limited access to personal protective equipment and essential medications.

Cabozantinib With Nivolumab Extended PFS in Patients With Advanced Recurring Endometrial Cancer

June 08, 2020

The study, presented at the virtual ASCO20, showed significant clinical benefit for patients with endometrial cancer who were treated with cabozantinib and nivolumab.

FDA OKs Atezolizumab Plus Bevacizumab for Frontline Treatment of Advanced Liver Cancer

June 01, 2020

Officials with the FDA approved atezolizumab (Tecentriq, Genentech) in combination with bevacizumab (Avastin) for the treatment of patients with unresectable or metastatic hepatocellular carcinoma who have not received prior systemic therapy.

Systematic Review Evaluates Cannabis, Cannabinoids in Palliative and Supportive Oncology Care

May 30, 2020

A systematic review of medical cannabis and cannabinoid use in oncology care demonstrated varied results. 

Adjuvant Osimertinib Therapy Delays Disease Recurrence in Localized NSCLC

May 30, 2020

Targeted therapy osimertinib (Tagrisso) demonstrated significant improvements in disease-free survival in patients with localized non-small cell lung cancer (NSCLC) who were treated following surgery.

ASCO20 Virtual: Pembrolizumab Doubles Progression-Free Survival for Certain Advanced Colorectal Cancer Types

May 29, 2020

The study marks the first time that the drug has demonstrated benefit for front-line therapy in patients with this type of colorectal cancer.

Study: Inclusion of Oncology Pharmacist Led to Financial, Clinical Benefits in Clinic

May 29, 2020

An outpatient multiple myeloma clinic benefited substantially from employing a clinical pharmacist.